Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Marshall

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|May 13, 2017
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosisJack Burks, Thomas S Marshall, Xiaolan Ye
The Journal of Prosthetic Dentistry|March 6, 2012
Supplementing retention through crown/preparation modification: an in vitro studyHal O'Kray, Thomas S Marshall, Thomas M Braun
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2008
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychoticsThomas S Marshall, Jeffery S McCombs, Dana Stafkey-Mailey
Clinical Drug Investigation|November 12, 2013
Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USAAmit Sharma, Thomas S Marshall, Samina S Khan, et al.
Clinical Drug Investigation|March 1, 2015
Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected]Mark Nuijten, Daniela P Roggeri, Alessandro Roggeri, et al.
Journal of Medical Economics|July 10, 2013
Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patientsAmit Sharma, Markus Ketteler, Thomas S Marshall, et al.
Journal of Drugs in Dermatology : JDD|June 3, 2010
Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitisCharu Taneja, Richard J Antaya, Ariel Berger, et al.
International Urology and Nephrology|August 15, 2013
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilitiesNing Wu, Thomas S Marshall, Luke Boulanger, et al.
Journal of Medical Economics|September 13, 2017
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's diseaseJulia Lowin, Kavita Sail, Rakhi Baj, et al.
Current Medical Research and Opinion|March 3, 2009
Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverageMiriam G Cisternas, Aimee J Foreman, Thomas S Marshall, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinicoeconomics and Outcomes Research : CEOR|May 13, 2017
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosisJack Burks, Thomas S Marshall, Xiaolan Ye
The Journal of Prosthetic Dentistry|March 6, 2012
Supplementing retention through crown/preparation modification: an in vitro studyHal O'Kray, Thomas S Marshall, Thomas M Braun
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2008
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychoticsThomas S Marshall, Jeffery S McCombs, Dana Stafkey-Mailey
Clinical Drug Investigation|November 12, 2013
Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USAAmit Sharma, Thomas S Marshall, Samina S Khan, et al.
Clinical Drug Investigation|March 1, 2015
Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected]Mark Nuijten, Daniela P Roggeri, Alessandro Roggeri, et al.
Journal of Medical Economics|July 10, 2013
Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patientsAmit Sharma, Markus Ketteler, Thomas S Marshall, et al.
Journal of Drugs in Dermatology : JDD|June 3, 2010
Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitisCharu Taneja, Richard J Antaya, Ariel Berger, et al.
International Urology and Nephrology|August 15, 2013
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilitiesNing Wu, Thomas S Marshall, Luke Boulanger, et al.
Journal of Medical Economics|September 13, 2017
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's diseaseJulia Lowin, Kavita Sail, Rakhi Baj, et al.
Current Medical Research and Opinion|March 3, 2009
Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverageMiriam G Cisternas, Aimee J Foreman, Thomas S Marshall, et al.
Pageof 2